Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

1.

Application of molecular profiling in clinical trials for advanced metastatic cancers.

Kummar S, Williams PM, Lih CJ, Polley EC, Chen AP, Rubinstein LV, Zhao Y, Simon RM, Conley BA, Doroshow JH.

J Natl Cancer Inst. 2015 Feb 6;107(4). pii: djv003. doi: 10.1093/jnci/djv003. Print 2015 Apr.

PMID:
25663694
[PubMed - in process]
2.

Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer.

Do K, Speranza G, Bishop R, Khin S, Rubinstein L, Kinders RJ, Datiles M, Eugeni M, Lam MH, Doyle LA, Doroshow JH, Kummar S.

Invest New Drugs. 2015 Feb 1. [Epub ahead of print]

PMID:
25637165
[PubMed - as supplied by publisher]
3.

Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer.

Kummar S, Fleming GF, Oza AM, Sullivan DM, Gandara DR, Naughton M, Villalona-Calero MA, Morgan R, Szabo PM, Youn A, Chen A, Ji JJ, Allen D, Lih CJ, Mehaffey MG, Walsh WD, McGregor PM 3rd, Steinberg SM, Williams PM, Kinders R, Conley BA, Simon RM, Doroshow JH.

Clin Cancer Res. 2015 Jan 14. pii: clincanres.2565.2014. [Epub ahead of print]

PMID:
25589624
[PubMed - as supplied by publisher]
4.

A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine.

Newman EM, Morgan RJ, Kummar S, Beumer JH, Blanchard MS, Ruel C, El-Khoueiry AB, Carroll MI, Hou JM, Li C, Lenz HJ, Eiseman JL, Doroshow JH.

Cancer Chemother Pharmacol. 2015 Mar;75(3):537-46. doi: 10.1007/s00280-014-2674-7. Epub 2015 Jan 8.

PMID:
25567350
[PubMed - in process]
5.

New, tolerable γ-secretase inhibitor takes desmoid down a notch.

Hughes DP, Kummar S, Lazar AJ.

Clin Cancer Res. 2015 Jan 1;21(1):7-9. doi: 10.1158/1078-0432.CCR-14-1660. Epub 2014 Oct 21.

PMID:
25336699
[PubMed - in process]
6.

Translational research in oncology--10 years of progress and future prospects.

Doroshow JH, Kummar S.

Nat Rev Clin Oncol. 2014 Nov;11(11):649-62. doi: 10.1038/nrclinonc.2014.158. Epub 2014 Oct 7.

PMID:
25286976
[PubMed - in process]
7.

Paraneoplastic neurologic manifestations of malignancies. Foreword.

Kummar S.

Curr Probl Cancer. 2014 Jul-Aug;38(4):114. doi: 10.1016/j.currproblcancer.2014.08.001. Epub 2014 Aug 12. No abstract available.

PMID:
25239544
[PubMed - in process]
8.

Validation of a hypoxia-inducible factor-1 alpha specimen collection procedure and quantitative enzyme-linked immunosorbent assay in solid tumor tissues.

Park SR, Kinders RJ, Khin S, Hollingshead M, Antony S, Parchment RE, Tomaszewski JE, Kummar S, Doroshow JH.

Anal Biochem. 2014 Aug 15;459:1-11. doi: 10.1016/j.ab.2014.04.025. Epub 2014 May 4.

PMID:
24799347
[PubMed - indexed for MEDLINE]
9.

Cabozantinib-induced thyroid dysfunction: a review of two ongoing trials for metastatic bladder cancer and sarcoma.

Yavuz S, Apolo AB, Kummar S, del Rivero J, Madan RA, Shawker T, Reynolds J, Celi FS.

Thyroid. 2014 Aug;24(8):1223-31. doi: 10.1089/thy.2013.0621. Epub 2014 Jun 5.

PMID:
24724719
[PubMed - in process]
10.

These tumors can be associated with known genetic syndromes, such as the von Hippel-Lindau or multiple endocrine neoplasia 2 syndromes, or they can arise sporadically. Foreword.

Kummar S.

Curr Probl Cancer. 2014 Jan-Feb;38(1):6. doi: 10.1016/j.currproblcancer.2014.02.001. Epub 2014 Feb 17. No abstract available.

PMID:
24636753
[PubMed - indexed for MEDLINE]
11.

Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors.

Jeong W, Rapisarda A, Park SR, Kinders RJ, Chen A, Melillo G, Turkbey B, Steinberg SM, Choyke P, Doroshow JH, Kummar S.

Cancer Chemother Pharmacol. 2014 Feb;73(2):343-8. doi: 10.1007/s00280-013-2362-z. Epub 2013 Nov 30.

PMID:
24292632
[PubMed - indexed for MEDLINE]
12.

Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors.

Jeong W, Park SR, Rapisarda A, Fer N, Kinders RJ, Chen A, Melillo G, Turkbey B, Steinberg SM, Choyke P, Doroshow JH, Kummar S.

Invest New Drugs. 2014 Apr;32(2):340-6. doi: 10.1007/s10637-013-0048-3. Epub 2013 Nov 16.

PMID:
24242862
[PubMed - indexed for MEDLINE]
13.

Current Problems in Cancer. Bone tumors in children and young adults. Foreword.

Kummar S.

Curr Probl Cancer. 2013 Jul-Aug;37(4):159. doi: 10.1016/j.currproblcancer.2013.07.001. No abstract available.

PMID:
24238579
[PubMed - indexed for MEDLINE]
14.

Wee1 kinase as a target for cancer therapy.

Do K, Doroshow JH, Kummar S.

Cell Cycle. 2013 Oct 1;12(19):3159-64. doi: 10.4161/cc.26062. Epub 2013 Aug 26. Review.

PMID:
24013427
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies.

Jeong W, Doroshow JH, Kummar S.

Curr Probl Cancer. 2013 May-Jun;37(3):110-44. doi: 10.1016/j.currproblcancer.2013.06.001. Review. No abstract available.

PMID:
23972982
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas.

Kummar S, Gutierrez ME, Anderson LW, Klecker RW Jr, Chen A, Murgo AJ, Doroshow JH, Collins JM.

Cancer Chemother Pharmacol. 2013 Oct;72(4):917-23. doi: 10.1007/s00280-013-2244-4. Epub 2013 Aug 3.

PMID:
23912694
[PubMed - indexed for MEDLINE]
17.

Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.

Shibata SI, Chung V, Synold TW, Longmate JA, Suttle AB, Ottesen LH, Lenz HJ, Kummar S, Harvey RD, Hamilton AL, O'Neil BH, Sarantopoulos J, LoRusso P, Rudek MA, Dowlati A, Mulkerin DL, Belani CP, Gandhi L, Lau SC, Ivy SP, Newman EM.

Clin Cancer Res. 2013 Jul 1;19(13):3631-9. doi: 10.1158/1078-0432.CCR-12-3214. Epub 2013 May 7.

PMID:
23653147
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

LC-MS/MS assay for the quantitation of the HDAC inhibitor belinostat and five major metabolites in human plasma.

Kiesel BF, Parise RA, Tjørnelund J, Christensen MK, Loza E, Tawbi H, Chu E, Kummar S, Beumer JH.

J Pharm Biomed Anal. 2013 Jul-Aug;81-82:89-98. doi: 10.1016/j.jpba.2013.03.025. Epub 2013 Apr 9.

PMID:
23644904
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Cediranib for metastatic alveolar soft part sarcoma.

Kummar S, Allen D, Monks A, Polley EC, Hose CD, Ivy SP, Turkbey IB, Lawrence S, Kinders RJ, Choyke P, Simon R, Steinberg SM, Doroshow JH, Helman L.

J Clin Oncol. 2013 Jun 20;31(18):2296-302. doi: 10.1200/JCO.2012.47.4288. Epub 2013 Apr 29.

PMID:
23630200
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Molecular targets in cancer therapy.

Kummar S, Doroshow JH.

Expert Rev Anticancer Ther. 2013 Mar;13(3):267-9. doi: 10.1586/era.12.170.

PMID:
23477512
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk